Webinar: Osmotic pumps - Powering precision in drug delivery

Language: English

Duration: 65 minutes

Format: Available on demand

In this third webinar of our MR series, experts from IMCD and IFF Pharma Solutions will explore the formulation principles behind osmotic pumps and targeted-release drug delivery. Attendees will gain insights into polymer selection, critical formulation parameters, and real-world applications that shape modern drug development strategies. 

Targeted drug delivery systems and osmotic pump technologies have revolutionized the way active pharmaceutical ingredients (APIs) are released, absorbed, and retained at the intended site of action. These innovations offer distinct advantages, such as improved bioavailability, enhanced therapeutic efficacy, and reduced systemic side effects. However, they also introduce challenges in formulation complexity, manufacturing feasibility, and cost efficiency.

Novel therapies, like gastric- and colon-retentive delivery systems, rely on pH sensitivity, gastric emptying patterns, and microbial interactions to maintain drug retention in specific regions of the gastrointestinal tract. On the other hand, osmotic pump tablets (OPT) enable precise, zero-order drug release independent of gastrointestinal motility, ensuring consistent plasma levels. By keeping drugs where they are most effective, OPTs reduces systemic toxicity, optimize absorption, and transform treatment strategies for conditions requiring sustained or site-specific drug release. 

Join us for this deep dive into the science behind controlled-release technologies and discover how to optimize your formulations for maximum therapeutic impact. 

 

Elizabeth Tocce is a lead applications scientist for IFF Pharma Solutions, where she heads technical marketing projects promoting the expertise of the Pharma Solutions business unit.

Elizabeth joined the IFF Pharma Solutions team in 2018 as a pharma application development scientist. In this role, she provided technical support to pharmaceutical customers and project leadership on growth and innovation projects using IFF’s pharmaceutical excipients. Prior to her roles with IFF, Elizabeth was a research and development scientist for the Dow Chemical Company’s Pharma & Food Solutions excipient business, where she led R&D projects in areas of specialty oral solid dosages and quality improvement.

Elizabeth received her Ph.D. in chemical and biological engineering from the University of Wisconsin in Madison.

After completing a BSc in Chemistry, Simon studied Biopolymer Mixtures for his PhD. This was followed by several academic research positions investigating super absorbent materials, carbon nanotube rheology, dental and medical materials, pulmonary drug delivery and protein-polysaccharide drug conjugates. ​After leaving academia, he spent five years in a global technical support role in the oral drug products group of a multinational pharmaceutical company, responsible for technology transfers, excipient introductions, process scale-up and troubleshooting. For the last 13 years, he has worked for excipient manufacturers and distribution companies in technical sales and scientific business development roles. 

Stay ahead in modified-release drug delivery with insights that bridge science, innovation, and market opportunity. To watch the video, please log in to MyIMCD. If you have any questions on the presented topics, feel free to fill in the form on this page or reach out to your dedicated IMCD contact person.